钠-葡萄糖协同转运蛋白 2（SGLT2）抑制剂可降低 PCI 后非糖尿病合并射血分数降低心衰（HFrEF）患者他汀类药物引起的异常血糖发生率。
SGLT2 inhibitors can reduce the incidence of abnormal blood glucose caused by statins in non-diabetes patients with HFrEF after PCI.
机构信息
Department of Cardiology, the Affiliated Hospital of Qingdao University, Qingdao, China.
出版信息
BMC Cardiovasc Disord. 2023 Jun 27;23(1):327. doi: 10.1186/s12872-023-03353-1.
BACKGROUND
Taking statins for a long time is associated with an increased risk of new-onset diabetes mellitus. Sodium-glucose cotransporter-2 (SGLT2) inhibitors can reduce insulin resistance and improve pancreatic β-cell function.
METHODS AND RESULTS
In total, 333 non-diabetes patients with heart failure with reduced ejection fraction (HFrEF) after percutaneous coronary intervention (PCI) are included. The enrolled patients are divided into a matched group (n = 198) and an SGLT2 inhibitors group (n = 135). There are no statistical differences in general information between the two groups before treatment. After a mean follow-up time of 13 months, abnormal blood glucose levels are significantly higher in the matched group than in the SGLT2 inhibitors group (6.06 vs. 0.74%, P < 0.05). There are no statistically significant differences in the alanine aminotransferase (ALT), uric acid (UA), and estimated glomerular filtration (eGFR) levels between the two groups.
CONCLUSION
SGLT2 inhibitors play a significant protective role in reducing the risk of statins-induced abnormal blood glucose in non-diabetes patients with HFrEF after PCI, without increasing the burden on the heart, kidneys, and liver.
背景
长期服用他汀类药物与新发糖尿病风险增加相关。钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂可降低胰岛素抵抗并改善胰岛β细胞功能。
方法和结果
共纳入 333 例经皮冠状动脉介入治疗（PCI）后射血分数降低的心力衰竭（HFrEF）且无糖尿病的患者。将纳入的患者分为匹配组（n=198）和 SGLT2 抑制剂组（n=135）。两组患者在治疗前的一般资料无统计学差异。经过平均 13 个月的随访后，匹配组的异常血糖水平明显高于 SGLT2 抑制剂组（6.06%比 0.74%，P<0.05）。两组间的丙氨酸氨基转移酶（ALT）、尿酸（UA）和估算肾小球滤过率（eGFR）水平无统计学差异。
结论
SGLT2 抑制剂在降低 PCI 后 HFrEF 非糖尿病患者他汀类药物引起的异常血糖风险方面具有显著保护作用，同时不会增加心脏、肾脏和肝脏的负担。
Zotero 插件